Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
CorMedix Inc. - Common Stock
(NQ:
CRMD
)
9.780
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 2, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about CorMedix Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
Talphera (TLPH) Q3 2025 Earnings Call Transcript
↗
November 13, 2025
Talphera (TLPH) Q3 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
CorMedix Stock Breaks Out To 2-Month High: Analysts Reset Price Targets After Blowout Q3 And Surging DefenCath Demand
↗
November 13, 2025
Via
Stocktwits
CorMedix Q3 Profit Soars As DefenCath Dialysis Demand Exceeds Expectations
↗
November 12, 2025
CorMedix posts strong Q3 results with $104 million in revenue, higher DefenCath sales, and raises 2025 guidance following Melinta integration progress.
Via
Benzinga
Pharming Group Posts Upbeat Q3 Results, Joins On Holding, BigBear.ai Holdings And Other Big Stocks Moving Higher On Wednesday
↗
November 12, 2025
Via
Benzinga
Cormedix Stock Soars Pre-Market After Earnings Beat, Higher Full-Year Guidance
↗
November 12, 2025
The company now expects pro forma net revenue for the full year in a range of $390 million to $410 million, higher than a Wall Street estimate of $283.66 million.
Via
Stocktwits
Topics
Earnings
Earnings Scheduled For November 12, 2025
↗
November 12, 2025
Via
Benzinga
CRMD Stock Is The Talk Of The Town Today: What’s The Latest 2025 Revenue Forecast?
↗
October 20, 2025
Via
Stocktwits
Analyst Expectations For Cormedix's Future
↗
September 09, 2025
Via
Benzinga
CorMedix Strikes $300M Deal For Melinta Therapeutics, Retail Calls It A ‘Wonderful Acquisition’
↗
August 07, 2025
Via
Stocktwits
CorMedix Inc. (NASDAQ:CRMD) Q3 2025 Earnings: Revenue Beat Offsets EPS Miss
↗
November 12, 2025
CorMedix Inc. (CRMD) Q3 2025 earnings show a revenue beat of $104.3M, but an EPS miss. The stock rose in pre-market trading on strong sales growth.
Via
Chartmill
CorMedix Inc (NASDAQ:CRMD) Fulfills Key Growth Stock Criteria from The Little Book
↗
November 11, 2025
CorMedix (CRMD) excels in a proven growth stock strategy, showing massive sales growth, strong earnings momentum, and solid profitability metrics.
Via
Chartmill
Top Stocks With Earnings This Week: Plug, Oklo, Circle And More
↗
November 10, 2025
Here's a look at this week's earnings reports that are most likely to be watched by retail investors, including Oklo, Plug and Circle.
Via
Benzinga
Beyond The Numbers: 4 Analysts Discuss Cormedix Stock
↗
October 21, 2025
Via
Benzinga
CorMedix Inc (NASDAQ:CRMD) Fits a Proven Growth Strategy with Strong Fundamentals
↗
October 21, 2025
CorMedix Inc. fits a proven growth investing strategy with explosive revenue growth, soaring profits, and strong analyst revisions, signaling high potential.
Via
Chartmill
CorMedix Inc (NASDAQ:CRMD) Identified as a Top Growth Stock Candidate
↗
September 29, 2025
CorMedix Inc (CRMD) identified as a top growth stock using Louis Navellier's strategy, showing explosive revenue growth, soaring earnings estimates, and strong profitability.
Via
Chartmill
CorMedix Inc (NASDAQ:CRMD) Embodies a Proven Growth Investing Strategy
↗
September 08, 2025
CorMedix (CRMD) excels in Louis Navellier's growth strategy with massive revenue growth, soaring earnings, and high ROE, making it a top stock to watch.
Via
Chartmill
10 Health Care Stocks Whale Activity In Today's Session
↗
September 02, 2025
Via
Benzinga
CORMEDIX INC (NASDAQ:CRMD) – A High-Growth Stock Aligned with Louis Navellier’s Investment Strategy
↗
August 18, 2025
Discover how CORMEDIX INC (CRMD) aligns with Louis Navellier’s growth investing strategy, showcasing strong earnings momentum, rapid revenue growth, and high ROE for potential stock gains.
Via
Chartmill
Elliott Management Bets Against S&P 500, Nasdaq 100, Nvidia Stock In Second Quarter
↗
August 14, 2025
Elliott Management places new bets against the market in the second quarter, while taking a new long position in Hewlett Packard Enterprise.
Via
Benzinga
Topics
Stocks
Deal Dispatch: Performance Food Group And Claire's Lead A Week Of Big Auctions, Retail Woes
↗
August 08, 2025
Performance Food rejects offer; Lufthansa drops Air Europa bid; NFL inks deal with ESPN; Claire's files bankruptcy amid retail struggles.
Via
Benzinga
Topics
Bankruptcy
CorMedix Inc (NASDAQ:CRMD) Reports Strong Q2 2025 Earnings, Beats Estimates and Announces Strategic Acquisition
↗
August 07, 2025
CorMedix Inc (CRMD) reported strong Q2 2025 earnings, beating revenue and EPS estimates, with shares rising in pre-market trading. The company also announced the acquisition of Melinta Therapeutics.
Via
Chartmill
Topics
Earnings
CorMedix Analyst Says Investors Could Be Further Rewarded
↗
June 30, 2025
CorMedix boosts Q2 sales forecast as a major dialysis client accelerates DefenCath use, prompting positive analyst coverage and growth outlook.
Via
Benzinga
This CorMedix Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Monday
↗
June 30, 2025
Via
Benzinga
Concentrix Posts Downbeat Earnings, Joins CorMedix And Other Big Stocks Moving Lower In Friday's Pre-Market Session
↗
June 27, 2025
Via
Benzinga
Stay updated with the stocks that are on the move in today's pre-market session.
↗
June 27, 2025
The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Via
Chartmill
CorMedix Stock Tumbles After $85M Stock Sale; But Retail Sees Bargain In DefenCath Bet
↗
June 27, 2025
The offering follows an upward revision to CorMedix’s Q2 revenue forecast, driven by faster-than-expected rollout of its FDA-approved DefenCath therapy across an extensive dialysis network.
Via
Stocktwits
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
June 26, 2025
Via
Benzinga
Get insights into the top gainers and losers of Thursday's after-hours session.
↗
June 26, 2025
After the closing bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
Via
Chartmill
Applied Materials To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Tuesday
↗
June 24, 2025
Via
Benzinga
CorMedix Lifts Q2 Outlook As Dialysis Partner Expands DefenCath Use; Needham Raises PT To $20
↗
June 23, 2025
DefenCath, CorMedix’s lead product, was launched in hospitals in April 2024 and in outpatient settings in July 2024 following FDA approval.
Via
Stocktwits
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
